Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?

Bone Marrow Transplantation, Published online: 25 November 2023; doi:10.1038/s41409-023-02155-5Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?

https://www.nature.com/articles/s41409-023-02155-5

Source: Bone Marrow Transplantation - November 25, 2023 Category: Hematology Authors: Jan Storek Julian Lindsay Source Type: research

More News: Bone Marrow Transplant | Hematology | Rituxan | Transplants